2010”N10ŒŽ—ÕŽžŠJÃŽó‘õŒ¤‹†R¸ˆÏˆõ‰ï@‰ï‹c‹L˜^‚ÌŠT—v | |||||||||
“ú@Žž | @ | 2010”N10ŒŽ27“úi…j15F30`15F45 | @ | @ | @ | @ | @ | ||
ê@Š | @ | “Æ—§s–@l@‘—§•a‰@‹@\@–kŠC“¹‚ª‚ñƒZƒ“ƒ^[3F ‰žÚŽº | @ | @ | @ | ||||
oÈŽÒ | ‹ß“¡•›‰@’·@ª–{ŠO•”ˆÏˆõ@ŠpˆäŠO•”ˆÏˆõ@ŽRé—Õ°Œ¤‹†•”’·@‚‹´–ò•¨—Ö@•”’·@ | @ | |||||||
@ | Œ´“cŒÄ‹zŠí“à‰Èˆã’·@‘ºãŽ––±•”’·@’†ŽRŠÅŒì•”’·@ûüè–ò܉Ȓ· | ||||||||
Œ‡ÈŽÒ | @ | ¼‹vŠO•”ˆÏˆõ@‰Á“¡“Š‡f—Õ”’·@ | @ | @ | @ | @ | @ | ||
ˆÏˆõ’· | @ | ‹ß“¡•›‰@’· | @ | @ | @ | @ | @ | @ | @ |
ƒIƒuƒU[ƒo[ | ‚È‚µ | @ | |||||||
Ž¡Œ±ŠÇ—Žº | @ | “à“¡@ŽOã@–x“c@àVŒû | @ | @ | @ | @ | @ | @ | |
ŠJ×vŒ |
@ | Ž¡Œ±R¸ˆÏˆõ‰ï‹Æ–±Žè‡‘‘æ5ð4€¬—§ | @ | @ | @ | @ | |||
yR@‹cz | @ | @ | @ | @ | @ | @ | |||
\¿ŽÒ | @ | ƒAƒXƒgƒ‰ƒ[ƒlƒJŠ”Ž®‰ïŽÐ | |||||||
Œö•\‰Û‘è–¼ | @ | “ú–{lisŒÅŒ`ˆ««Žîᇊ³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚½AZD4547‚̈À‘S«A”E—e«A‘Ì“à“®‘ÔA‹y‚ÑRŽîᇌø‰Ê‚ðŒŸ“¢‚·‚é”ñ–ÓŒŸ—p—Ê‘Q‘‘½Ž{Ý‹¤“¯‘æ‡T‘ŠŽŽŒ± | |||||||
R‹c“à—e | Ž¡Œ±‚ÌŒp‘±ŽÀŽ{‚̑Ó–«‚ɂ‚¢‚ÄR‹c‚µ‚½B | @ | |||||||
@ | Ž––±‹Ç‚æ‚èAˆÈ‰º‚Ì€–ڂɂ‚¢‚Äà–¾‚ª‚ ‚è˜_‹c‚ðs‚Á‚½B 1)Ž¡Œ±‚ÉŠÖ‚·‚é•ÏXiŽ¡Œ±ŽÀŽ{Œv‰æ‘“™‰ü’ùA“¯ˆÓà–¾•¶‘‰ü’ùj |
||||||||
R‹cŒ‹‰Ê | @ | ³”F | i‚‹´ˆÏˆõ‚ðœ‚j | @ | @ | @ | @ | @ | |
\¿ŽÒ | @ | ƒtƒ@ƒCƒU[Š”Ž®‰ïŽÐ | |||||||
Œö•\‰Û‘è–¼ | @ | A Randomized Double-blind Placebo-Controlled Trial of Neratinib (HKI-272) After Trastuzumab in Women With Early-Stage HER-2/neu Overexpressed/Amplified Breast Cancer | |||||||
R‹c“à—e | Ž¡Œ±‚ÌŒp‘±ŽÀŽ{‚̑Ó–«‚ɂ‚¢‚ÄR‹c‚µ‚½B | @ | |||||||
@ | Ž––±‹Ç‚æ‚èAˆÈ‰º‚Ì€–ڂɂ‚¢‚Äà–¾‚ª‚ ‚è˜_‹c‚ðs‚Á‚½B 1)Ž¡Œ±‚ÉŠÖ‚·‚é•ÏXiŒ_–ñ“à—e•ÏXj |
||||||||
R‹cŒ‹‰Ê | @ | ³”F | iŽRéˆÏˆõ‚ðœ‚j | @ | @ | @ | @ | @ | |
\¿ŽÒ | @ | ƒtƒ@ƒCƒU[Š”Ž®‰ïŽÐ | |||||||
Œö•\‰Û‘è–¼ | @ | A Phase 3, Randomized, Open-Label, Two-Arm Study of Neratinib Plus Paclitaxel Versus Trastuzumab Plus Paclitaxel as First-Line Treatment for ErbB-2-Positive Locally Recurrent or Metastatic Breast Cancer | |||||||
R‹c“à—e | Ž¡Œ±‚ÌŒp‘±ŽÀŽ{‚̑Ó–«‚ɂ‚¢‚ÄR‹c‚µ‚½B | @ | |||||||
@ | Ž––±‹Ç‚æ‚èAˆÈ‰º‚Ì€–ڂɂ‚¢‚Äà–¾‚ª‚ ‚è˜_‹c‚ðs‚Á‚½B 1)Ž¡Œ±‚ÉŠÖ‚·‚é•ÏXiŒ_–ñ“à—e•ÏXj |
||||||||
R‹cŒ‹‰Ê | @ | ³”F | iŽRéˆÏˆõ‚ðœ‚j | @ | @ | @ | @ | @ |